Please assess the completion status of the following clinical trial:

Trial Title: BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment~2. Indication for a treatment with platinum therapy as judged by the investigator~3. Age 18 years or older~4. Written informed consent consistent with ICH-GCP and local legislation~5. ECOG performance score lower or equal 2~6. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous systemic anti-cancer therapies or radiotherapies (except alopecia grade 2)~Exclusion criteria:~1. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol~2. Pregnancy or breastfeeding~3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV I/II~4. Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months~5. Second malignancy currently requiring another anti-cancer therapy~6. ANC less than 1500 / mm3~7. Platelet count less than 100 000 / mm3~8. Bilirubin greater than 1.5 mg / dl (\> 26 micromol / L, SI unit equivalent) (except Gilbert's syndrome)~9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)~10. Serum creatinine greater than 1.5 mg / dl (\> 132 micromol / L, SI unit equivalent) or creatinine clearance \<70ml/min (as calculated according to Cockcroft-Gault formula for GFR estimate)~11. Known history of relevant QT-prolongation, e.g. long QT-syndrome~12. Pre-existing clinically relevant hearing loss~13. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception~14. Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks before start of therapy or concomitantly with this trial~15. Systemic anti-cancer therapy or radiotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.~16. Patients unable to comply with the protocol~17. Active alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A. BI 6727-cisplatin (Type: EXPERIMENTAL): patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
- B. BI 6727-carboplatin (Type: EXPERIMENTAL): patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).